Number of Pretransplant Therapeutic Plasma Exchange Sessions Increase the Recurrence Risk of Hepatocellular Carcinoma in ABO-Incompatible Living Donor Liver Transplantation
Transplant International · 2025
DOI: 10.3389/ti.2025.14304 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant International, 2025. Verfasst von Young Jin Yoo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Research Institute for Transplantation, Yonsei University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Transplantation, Liver Neoplasms, ABO Blood-Group System. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Previous studies have reported comparable oncologic outcome between ABO-incompatible (ABOi) living donor liver transplantation (LDLT) and ABO-compatible (ABOc) LDLT in patients with hepatocellular carcinoma (HCC). We aimed to analyze the relationship between number of therapeutic plasma exchanges (TPE) before LDLT and HCC outcomes in ABOi LDLT. In this single-center retrospective study, 428 adult LDLT recipients with HCC were categorized into three groups according to ABO incompatibility and the number of pretransplant TPE: ABOc (n = 323), ABOi/TPE ≤5 (n = 75), and ABOi/TPE ≥6 (n = 30). The RFS and HCC recurrence rates were compared. Three groups showed similar characteristics in most demographics, pretransplant tumor markers and pathologies. The median initial isoagglutinin (IA) titer was 1:64 (range negative-1:512) in ABOi/TPE ≤5 group and 1:512 (range 1:128–1:4,096) in ABOi/TPE ≥6 group. Five-year RFS was significantly lower (75.7% vs. 72.7% vs. 50.0%, P = 0.005) and HCC recurrence was significantly higher in the ABOi/TPE ≥6 group than in the other groups(16.4% vs. 17.0% vs. 39.4%, P = 0.014). In multivariable Cox regression analysis, ABOi/TPE ≥6 was an independent risk factor for RFS (aHR 1.99, 95% CI:1.02–3.86, P = 0.042) and HCC recurrence (aHR 2.42, 95% CI:1.05–5.57, P = 0.037). More than six pretransplant TPE sessions may increase the risk of HCC recurrence after ABOi LDLT. Reducing TPE sessions to fewer than six should be considered while maintaining immunological stability through IA titer control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Research Institute for Transplantation, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Division of Transplant Surgery, Department of Surgery, Yongin Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Department of Surgery, Graduate School of Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Zitieren
APA
Yoo, Y. J., Kim, D. G., Min, E. K., Yim, S. H., Choi, M. C., Koh, H. H., Kang, M., Lee, J. G., Kim, M. S., & Joo, D. J. (2025). Number of Pretransplant Therapeutic Plasma Exchange Sessions Increase the Recurrence Risk of Hepatocellular Carcinoma in ABO-Incompatible Living Donor Liver Transplantation. Transplant International. https://doi.org/10.3389/ti.2025.14304
Vancouver
Yoo YJ, Kim DG, Min EK, Yim SH, Choi MC, Koh HH, et al. Number of Pretransplant Therapeutic Plasma Exchange Sessions Increase the Recurrence Risk of Hepatocellular Carcinoma in ABO-Incompatible Living Donor Liver Transplantation. Transplant International. 2025. doi:10.3389/ti.2025.14304
BibTeX
@article{Yoo2025,
author = {Yoo, Young Jin and Kim, Deok-Gie and Min, Eun-Ki and Yim, Seung Hyuk and Choi, Mun Chae and Koh, Hwa-Hee and Kang, Minyu and Lee, Jae Geun and Kim, Myoung Soo and Joo, Dong Jin},
title = {Number of Pretransplant Therapeutic Plasma Exchange Sessions Increase the Recurrence Risk of Hepatocellular Carcinoma in ABO-Incompatible Living Donor Liver Transplantation},
journal = {Transplant International},
year = {2025},
doi = {10.3389/ti.2025.14304}
}
EUVIMED